Overview of China's Market Approval Policy Med Insurance Payment System

Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.

In this whitepaper, hear from Parexel rare disease consultants on the following topics:

  • Relevant Policies on Expedited Approval of Rare Disease Drugs 
  • An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs

Open PDF

Return to Insights Center